Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen

Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term